Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Or
Select a campus/region

Barry J Byrne, MD, PhD

Pediatric Cardiologist

Photo of Barry J Byrne

About me

Dr. Barry Byrne is the Associate Chair of Pediatrics and Director of the Powell Gene Therapy Center at the University of Florida. After obtaining a B.S. degree in Chemistry from Denison University, he pursued his medical education, as well as a Ph.D. in Microbiology and Immunology, at the University of Illinois. He completed his pediatric residency, cardiology fellowship training and post-doctoral training in Biological Chemistry at Johns Hopkins University. Joining the University of Florida in 1997, he has served in a variety of clinical, research and educational roles, and is now the Earl and Christy Powell University Chair in Genetics.

Dr. Byrne is currently conducting numerous clinical research studies for a variety of rare diseases, with specific attention to developing therapies for inherited muscle disease. As a pediatric cardiologist, his focus is on conditions that lead to skeletal muscle weakness, cardiac dysfunction and respiratory dysfunction. His research team has made significant contributions to the understanding and treatment of Pompe disease, a type of muscular dystrophy resulting from abnormal glycogen accumulation in the muscle. His current research has focused on developing new therapies using the missing cellular protein or the corrective gene to restore muscle function in Pompe, Duchenne muscular dystrophy and other inherited myopathies.

My locations

Active clinical trials

Sarepta 4658-402

This study will be comprised of 2 parts: Part 1 (dose escalation) will be conducted to evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram [mg/kg] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2…

Investigator
Barry J Byrne
Status
Accepting Candidates
Ages
4 Years - 13 Years
Sexes
Male
Pfizer Early Stage GT

The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study

Investigator
Barry J Byrne
Status
Accepting Candidates
Ages
2 Years - 3 Years
Sexes
Male
ATB200-08

This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-naïve pediatric subjects with IOPD.

Investigator
Barry J Byrne
Status
Accepting Candidates
Ages
N/A - 17 Years
Sexes
All
View all of Dr. Byrne's active clinical trials

My research

Top areas of exploration

  • Genetic Therapy , 78 publications
  • Genetic Vectors , 77 publications
  • Glycogen Storage Disease Type II , 56 publications
  • Muscle, Skeletal , 40 publications

Research activity

336 publications

20,243 citations

Why is this important?
View more of Barry Byrne's research activity

Search our accepted insurances list

Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.

See all

My areas of focus

Our team provides fully integrated research and innovative clinical care in rare diseases where there may be no alternative therapies.

—  Dr. Barry J Byrne

Stories and news

View more stories related to Barry Byrne